Current Drug Targets

Francis J. Castellino
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556
USA

Back

Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases

Author(s): Stephen J. Shuttleworth, Sarah G. Bailey, Paul A. Townsend.

Abstract:

The development of Histone Deacetylase (HDAC) inhibitors has, until recently, principally been driven by their potential as anti-cancer agents. However, there is emerging evidence that HDAC inhibitors could have utility in the treatment of chronic immune and inflammatory disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, airway hyperresponsiveness and organ transplant rejection. Here we discuss the merits of various, structurally-distinct HDAC inhibitors as potential anti-inflammatory therapeutics and provide examples of the novel medicinal chemistry approaches being undertaken to realize HDAC as a druggable target in this clinical setting.

Keywords: Histone deacetylases, inhibitors, inflammation, immune disease, FK228, deacetylases, multiple sclerosis, rheumatoid arthritis, psoriasis, histones, nuclear proteins, T-cell lymphoma, (FDA), GM-CSF, TNFα, TGFβ, (MMPs), iNOS, IL-1β, IFN-, (Tregs), Cyclosporin-A, IL-2, (ZEB), (CtBP), CD4+ T, FR276457, (GVHD), (T-cell depletion), phosphorylation, (IBD), (SLE), CD28, RASFs, KBH-A42, Trichostatin-A, Vorinostat, chemokines, CTCL

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 11
ISSUE: 11
Year: 2010
Page: [1430 - 1438]
Pages: 9
DOI: 10.2174/1389450111009011430
Price: $58